Samuel Suzuki

768 total citations
22 papers, 460 citations indexed

About

Samuel Suzuki is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Samuel Suzuki has authored 22 papers receiving a total of 460 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 7 papers in Genetics. Recurrent topics in Samuel Suzuki's work include Advanced Breast Cancer Therapies (7 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Colorectal Cancer Treatments and Studies (3 papers). Samuel Suzuki is often cited by papers focused on Advanced Breast Cancer Therapies (7 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Colorectal Cancer Treatments and Studies (3 papers). Samuel Suzuki collaborates with scholars based in United States, Spain and France. Samuel Suzuki's co-authors include Ian McCaffery, Elwyn Loh, Jennifer Gansert, Jesse McGreivy, William Jacot, J.F.R. Robertson, Hugues Bourgeois, Hagen F. Kennecke, Min Zhu and Jean-Marc Ferrero and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Samuel Suzuki

21 papers receiving 452 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Samuel Suzuki United States	9	228	214	130	113	102	22	460
Jamileh Hashemi Sweden	16	344 1.5×	252 1.2×	49 0.4×	40 0.4×	114 1.1×	26	575
M.C. Cox United States	10	180 0.8×	91 0.4×	177 1.4×	19 0.2×	74 0.7×	23	429
Gillianne Lai Singapore	5	190 0.8×	122 0.6×	197 1.5×	60 0.5×	106 1.0×	18	374
F Kémény France	8	98 0.4×	218 1.0×	52 0.4×	85 0.8×	115 1.1×	16	704
Hari A. Deshpande United States	10	136 0.6×	120 0.6×	90 0.7×	80 0.7×	39 0.4×	46	363
Pritesh Trivedi United Kingdom	11	189 0.8×	139 0.6×	83 0.6×	13 0.1×	88 0.9×	20	402
Bhumsuk Keam South Korea	9	312 1.4×	98 0.5×	134 1.0×	247 2.2×	56 0.5×	17	568
Bernardo Goulart United States	8	294 1.3×	98 0.5×	75 0.6×	342 3.0×	43 0.4×	10	566
Jessica Giorcelli Italy	12	99 0.4×	113 0.5×	125 1.0×	101 0.9×	166 1.6×	16	428
DC Betticher United Kingdom	6	289 1.3×	300 1.4×	89 0.7×	20 0.2×	94 0.9×	13	508

Countries citing papers authored by Samuel Suzuki

Since Specialization

Citations

This map shows the geographic impact of Samuel Suzuki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samuel Suzuki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samuel Suzuki more than expected).

Fields of papers citing papers by Samuel Suzuki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samuel Suzuki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samuel Suzuki. The network helps show where Samuel Suzuki may publish in the future.

Co-authorship network of co-authors of Samuel Suzuki

This figure shows the co-authorship network connecting the top 25 collaborators of Samuel Suzuki. A scholar is included among the top collaborators of Samuel Suzuki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samuel Suzuki. Samuel Suzuki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wesolowski, Robert, Hope S. Rugo, Jennifer M. Specht, et al.. (2025). Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer. Clinical Cancer Research. 31(19). 4040–4048.

Layman, Rachel M., Hyo S. Han, Hope S. Rugo, et al.. (2024). Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study. The Lancet Oncology. 25(4). 474–487. 31 indexed citations

Rugo, Hope S., Robert Wesolowski, Erica Stringer-Reasor, et al.. (2023). 204P Phase Ib study of gedatolisib plus palbociclib and endocrine therapy in women with hormone receptor positive advanced breast cancer: Updated results in treatment naïve patients. ESMO Open. 8(1). 101393–101393. 1 indexed citations

Hurvitz, Sara A., Fabrice André, Massimo Cristofanilli, et al.. (2023). Abstract CT063: A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1). Cancer Research. 83(8_Supplement). CT063–CT063. 2 indexed citations

Barillà, C., Samuel Suzuki, András Rab, et al.. (2021). 667: Development of an iPSC-based airway epithelial platform for evaluating patient-specific responses to modulators. Journal of Cystic Fibrosis. 20. S316–S316. 1 indexed citations

Linnemann, Rachel W., George M. Solomon, William B. Driggers, et al.. (2021). 572: Clinical and iPSC-derived airway epithelial responses to elexacaftor/tezacaftor/ivacaftor in CF patients without an approved modulator. Journal of Cystic Fibrosis. 20. S271–S271. 1 indexed citations

Jazaeri, Amir A., Robert P. Edwards, Robert M. Wenham, et al.. (2018). A phase 2, multicenter study to evaluate the efficacy and safety using autologous tumor infiltrating lymphocytes (LN-145) in patients with recurrent, metastatic, or persistent cervical carcinoma.. Journal of Clinical Oncology. 36(15_suppl). TPS5604–TPS5604. 3 indexed citations

Jazaeri, Amir A., Robert P. Edwards, Emese Zsíros, et al.. (2018). A phase II, multicenter study to evaluate the efficacy and safety using autologous tumor infiltrating lymphocytes (LN-145) in patients with recurrent, metastatic, or persistent cervical carcinoma. Gynecologic Oncology. 149. 118–118. 3 indexed citations

Leidner, Rom S., Ammar Sukari, Christine H. Chung, et al.. (2018). A phase 2, multicenter study to evaluate the efficacy and safety of autologous tumor infiltrating lymphocytes (LN-145) for the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC).. Journal of Clinical Oncology. 36(15_suppl). TPS6096–TPS6096. 8 indexed citations

10.

Coutré, Steven, John C. Byrd, Peter Hillmen, et al.. (2016). Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). Blood. 128(22). 4383–4383. 6 indexed citations

11.

Fowler, Nathan, Loretta J. Nastoupil, Sven de Vos, et al.. (2016). Ibrutinib Combined with Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Arm 1 + Arm 2 Results from a Multicenter, Open-Label Phase 2 Study. Blood. 128(22). 1804–1804. 6 indexed citations

12.

Barr, Paul M., Jennifer R. Brown, Peter Hillmen, et al.. (2015). Dose adherence and baseline exposure analysis of the ibrutinib 420 mg dose administered to patients with previously treated chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 33(15_suppl). 7012–7012. 6 indexed citations

13.

Fowler, Nathan, Loretta J. Nastoupil, Sven de Vos, et al.. (2015). Ibrutinib Plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study. Blood. 126(23). 470–470. 23 indexed citations

14.

McCaffery, Ian, Yanyan Tudor, Hongjie Deng, et al.. (2013). Putative Predictive Biomarkers of Survival in Patients with Metastatic Pancreatic Adenocarcinoma Treated with Gemcitabine and Ganitumab, an IGF1R Inhibitor. Clinical Cancer Research. 19(15). 4282–4289. 54 indexed citations

15.

Cohn, Allen Lee, Josep Tabernero, Joan Maurel, et al.. (2013). A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer. Annals of Oncology. 24(7). 1777–1785. 74 indexed citations

16.

Robertson, J.F.R., Jean-Marc Ferrero, Hugues Bourgeois, et al.. (2013). Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial. The Lancet Oncology. 14(3). 228–235. 137 indexed citations

17.

Lu, Jianqin, Hongjie Deng, Rui Tang, et al.. (2011). Exposure-response (E-R) analysis to facilitate phase III (P3) dose selection for ganitumab (GAN, AMG 479) in combination with gemcitabine (G) to treat metastatic pancreatic cancer (mPC).. Journal of Clinical Oncology. 29(15_suppl). 4049–4049. 5 indexed citations

18.

Ferrero, J-M, Hugues Bourgeois, Hagen F. Kennecke, et al.. (2010). Abstract S1-4: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of AMG 479 With Exemestane (E) or Fulvestrant (F) in Postmenopausal Women With Hormone-Receptor Positive (HR+) Metastatic (M) or Locally Advanced (LA) Breast Cancer (BC). Cancer Research. 70(24_Supplement). S1–4. 39 indexed citations

19.

Cohn, Allen Lee, Deborah A. Smith, Marcus A. Neubauer, et al.. (2008). Panitumumab (pmab) regimen evaluation in colorectal cancer to estimate primary response to treatment (PRECEPT): Effect of KRAS mutation status on second-line treatment (tx) with pmab and FOLFIRI. Journal of Clinical Oncology. 26(15_suppl). 4127–4127. 11 indexed citations

20.

Swiatecka‐Urban, Agnieszka, Clotilde Druck Garcia, Samuel Suzuki, et al.. (2001). Basiliximab induction improves the outcome of renal transplants in children and adolescents. Pediatric Nephrology. 16(9). 693–696. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact